Dr Agarwals Eye Hospital per share figures

Share price at each year-end
Tap a line for its trendCurrentlast closeFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹147.02₹147.02₹116.28₹98.64₹78.55
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹147.02₹147.02₹116.28₹98.64₹78.55
₹726.29₹726.29₹445.99₹334.37₹241.14
₹987.55₹987.55₹845.02₹679.37₹569.96
——₹201.03₹191.00₹148.12
——₹201.03₹191.00₹148.12
——₹5.00₹5.49₹3.00
0.50.50.50.50.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

DRAGARWQ₹5,299.50

Dr Agarwals Eye Hospital Limited

· Pharma & Health
₹ CrorePeersKMCSHILKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDMcap ₹2,527 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current
last close
Basic EPS78.5598.64116.28147.02147.02
Diluted EPS78.5598.64116.28147.02147.02
Book Value per Share241.14334.37445.99726.29726.29
Revenue per Share569.96679.37845.02987.55987.55
Cash Flow per Share148.12191.00201.03——
Free Cash Flow per Share148.12191.00201.03——
Dividends per Share3.005.495.00——
Shares Outstanding (cr)0.50.50.50.50.5
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.